Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02199197 · ClinicalTrials.gov registry record · Phase 2
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT02199197 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 49 participants.
The verdict
NCT02199197, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
Study of Radium Ra 223 dichloride with enzalutamide compared to enzalutamide alone in men with metastatic castration refractory prostate cancer
Interventions
- DRUG Enzalutamide
- DRUG Radium Ra 223 Dichloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2014-06-25 |
| Est. Completion | 2019-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02199197
The ClinicalTrials.gov registry entry for NCT02199197 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enzalutamide is the first listed.
NCT02199197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02199197 about?
NCT02199197 is a clinical study titled "Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer". Study of Radium Ra 223 dichloride with enzalutamide compared to enzalutamide alone in men with metastatic castration refractory prostate cancer
What is the current status of trial NCT02199197?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2014-06-25. Estimated completion is 2019-10-03.
What interventions are being tested in trial NCT02199197?
The interventions under investigation include: Enzalutamide (DRUG), Radium Ra 223 Dichloride (DRUG).
Who is sponsoring clinical trial NCT02199197?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.